Insmed, Inc. $INSM Shares Sold by Orion Porfolio Solutions LLC

Orion Porfolio Solutions LLC lessened its position in shares of Insmed, Inc. (NASDAQ:INSM) by 12.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,693 shares of the biopharmaceutical company’s stock after selling 5,124 shares during the period. Orion Porfolio Solutions LLC’s holdings in Insmed were worth $5,284,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in INSM. Vanguard Group Inc. raised its position in shares of Insmed by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares in the last quarter. Norges Bank bought a new position in Insmed during the second quarter worth $194,728,000. Artisan Partners Limited Partnership boosted its holdings in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period. Orbis Allan Gray Ltd acquired a new position in Insmed in the second quarter worth $153,389,000. Finally, Qube Research & Technologies Ltd bought a new stake in Insmed during the second quarter valued at $108,898,000.

Insmed Stock Performance

INSM stock opened at $140.13 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The stock has a market capitalization of $30.21 billion, a price-to-earnings ratio of -21.86 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock’s fifty day moving average is $158.58 and its two-hundred day moving average is $165.58.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the prior year, the company posted ($1.32) EPS. The firm’s revenue was up 152.6% on a year-over-year basis. On average, research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on INSM. Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. Wells Fargo & Company decreased their price target on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating for the company in a report on Friday, February 20th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. UBS Group dropped their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $207.52.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. This represents a 5.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the sale, the insider owned 41,754 shares in the company, valued at $7,315,300.80. The trade was a 67.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 189,651 shares of company stock valued at $31,784,545 over the last three months. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.